Prognostic value of pretreatment ¹⁸F-FDG PET/CT and human papillomavirus type 16 testing in locally advanced oropharyngeal squamous cell carcinoma

Eur J Nucl Med Mol Imaging. 2012 Nov;39(11):1673-84. doi: 10.1007/s00259-012-2186-9. Epub 2012 Aug 2.

Abstract

Purpose: Human papillomavirus type 16 (HPV-16) positivity is associated with favourable survival in oropharyngeal squamous cell carcinoma (OPSCC). We report here a study of the prognostic significance of (18)F-FDG PET/CT functional parameters and HPV-16 infection in OPSCC patients.

Methods: We retrospectively analysed 60 patients with stage III or IV OPSCC who had had a pretherapy (18)F-FDG PET/CT scan and had completed concurrent chemoradiotherapy (n = 58) or curative radiotherapy (n = 2). All patients were followed up for ≥24 months or until death. We determined total lesion glycolysis (TLG) and the maximal standardized uptake values (SUV(max)) of the primary tumour and neck lymph nodes from the pretherapy (18)F-FDG PET/CT scan. Optimal cut-offs of the (18)F-FDG PET/CT parameters were obtained by receiver operating characteristic (ROC) curve analyses. Pretherapy tumour biopsies were studied by polymerase chain reaction to determine HPV infection status.

Results: The pretherapy tumour biopsies were positive for HPV-16 in 12 patients (20.0 %). Cox regression analyses revealed HPV-16 positivity and tumour TLG >135.3 g to be independently associated with overall survival (p = 0.027 and 0.011, respectively). However, only tumour TLG >135.3 g was independently associated with progression-free survival, disease-free survival and locoregional control (p = 0.011, 0.001 and 0.034, respectively). A scoring system was formulated to define distinct overall survival groups using tumour TLG and HPV-16 status. Patients positive for HPV-16 and with tumour TLG ≤135.3 g experienced better survival than those with tumour TLG >135.3 g and no HPV infection (p = 0.001).

Conclusion: Tumour TLG was an independent predictor of survival in patients with locally advanced OPSCC. A scoring system was developed and may serve as a risk stratification strategy for guiding therapy.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma, Squamous Cell / diagnosis
  • Carcinoma, Squamous Cell / diagnostic imaging*
  • Carcinoma, Squamous Cell / virology
  • Female
  • Fluorodeoxyglucose F18*
  • Human Papillomavirus DNA Tests
  • Human papillomavirus 16 / isolation & purification*
  • Humans
  • Male
  • Middle Aged
  • Multimodal Imaging*
  • Oropharyngeal Neoplasms / diagnosis
  • Oropharyngeal Neoplasms / diagnostic imaging*
  • Oropharyngeal Neoplasms / virology
  • Papillomavirus Infections / diagnosis*
  • Positron-Emission Tomography*
  • Prognosis
  • Radiopharmaceuticals*
  • Retrospective Studies
  • Tomography, X-Ray Computed*

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18